Table 1 Background, clinical features, laboratory data, and curative effect of patients with PVT treated with anticoagulants.
From: Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis
Edoxaban (n = 43) | Warfarin (n = 17) | p-value | |
|---|---|---|---|
Age, years (IQR) | 69 (53–74) | 68 (62–73) | 0.909 |
Gender, male/female | 28/15 | 11/6 | 0.976 |
Etiology, HBV or HCV/NBNC | 23/20 | 12/5 | 0.226 |
Child–Pugh grade, A/B or C (B/C) | 13/25/5 | 5/11/1 | 0.950 |
Time from PVT to treatment, days (IQR) | 21 (15–492) | 13 (3–35) | 0.104 |
Median percentage of portal vein lumen occupied, % (IQR) | 100 (65.1–100) | 100 (85.7–100) | 0.506 |
Localization of PVT, MPV/others | 33/10 | 11/6 | 0.342 |
Total bilirubin, mg/dL | 0.9 (0.7–1.7) | 1.1 (0.7–1.8) | 0.889 |
Aspartate aminotransferase, IU/L | 49 (36–65) | 49.5 (36.3–67.3) | 0.605 |
Alanine aminotransferase, IU/L | 28 (19.5–42) | 28 (21–40) | 0.831 |
Albumin, g/dL | 3.1 (2.7–3.5) | 3 (2.7–3.4) | 0.576 |
Platelet count, × 104/μL | 11.3 (6.6–15.6) | 9.1 (5.9–13.8) | 0.398 |
Prothrombin activity, % | 65 (53.5–84) | 65 (59.0–73.0) | 0.755 |
Activated partial thromboplastin time, ng/mL | 31.5 (28.8–35) | 32.9 (31.2–33.8) | 0.536 |
Ascites, yes/no | 29/14 | 10/7 | 0.528 |
Encephalopathy, yes/no | 41/2 | 1/16 | 0.844 |
Esophageal varix, yes/no | 35/8 | 15/2 | 0.522 |
Hepatocellular carcinoma, yes/no | 34/9 | 10/8 | 0.247 |
